key: cord-1054194-7e3cobil
authors: Sayeed, Hasan M.; Lee, Eun‐So; Byun, Hae‐Ok; Sohn, Seonghyang
title: The role of CCR1 and therapeutic effects of anti‐CCL3 antibody in herpes simplex virus‐induced Behçet's disease mouse model
date: 2019-09-08
journal: Immunology
DOI: 10.1111/imm.13102
sha: 2cc5cccb3c6f69704f97a19e680fe3e16496beff
doc_id: 1054194
cord_uid: 7e3cobil

Behçet's disease (BD) is a chronic systemic inflammatory disease with unclear etiopathogenesis. Although gene variants of CC chemokine receptor type 1 (CCR1) have been reported, the protein expression of CCR1 in patients with BD remains unclear. The objective of this study was to analyze the frequencies of CCR1(+) cells in a herpes simplex virus‐induced mouse model of BD. The frequencies of CCR1(+) cells on the surface and in the cytoplasm of peripheral blood mononuclear cells and lymph nodes were analyzed by flow cytometry. The CCR1(+) cells were significantly down‐regulated in BD mice compared with the normal control and symptom‐free control mice. Colchicine and pentoxifylline treatment improved the symptoms of BD and increased the frequencies of CCR1(+) cells in BD mice. Treatment with chemokine CC motif ligand 3 (CCL3), a ligand of CCR1, caused BD symptoms to deteriorate in 10 of 16 BD mice (62·5%) via down‐regulation of CCR1(+) cells. Anti‐CCL3 antibody treatment ameliorated BD symptoms in 10 of 20 mice (50%) and significantly decreased the disease severity score compared with CCL3‐treated BD mice (P = 0·01) via up‐regulation of CCR1(+) cell frequencies. In patients with BD, plasma levels of CCL3 in an active state were significantly higher than in healthy control individuals (P = 0·02). These results show that the up‐regulation of CCR1(+) cells was related to the control of systemic inflammation of BD in mouse models.

Behc ßet's disease (BD) is a chronic systemic inflammatory disease with unclear etiopathogenesis. Gene variants of CC chemokine receptor type 1 (CCR1) in patients with BD have been identified by genome-wide association studies. 1, 2 However, the CCR1 protein expression in patients with BD or in mouse models remains unclear.

CC chemokine receptor type 1 is expressed in cells of the immune system, including lymphocytes, monocytes, neutrophils and dendritic cells. 3, 4 It is involved in host defense, hematopoiesis, T helper type 1/2 (Th1/2) cell balance, and chemotaxis. 5, 6 The CCR1 expression is correlated with various inflammatory diseases, including rheumatoid arthritis, 7 asthma 8 and lupus nephritis. 9 CCR1 knockout (À/À) mice show reduced pulmonary inflammation, 10 and prolonged allograft survival. 11 CCR1 polymorphism might be a general risk factor for autoimmune or inflammatory disease. CCR1 antagonists have been used in clinical trials to treat multiple sclerosis, psoriasis and rheumatoid arthritis. 12 Herpes simplex virus (HSV) has been reported as an etiological factor in BD. [13] [14] [15] A mouse model of HSV-induced inflammatory BD was developed and used in various studies. [16] [17] [18] [19] The objective of the present study was to determine the expression of CCR1 in mice with inflammatory BD symptoms and to investigate whether CCR1 was regulated by ligands, agonists or antagonists. Flow Abbreviation: BD, Behc ßet's disease; BDN, herpes simplex virus-inoculated, but asymptomatic healthy mice; CCL3, chemokine CC motif ligand 3; CCR1, CC chemokine receptor type 1; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-10, interleukin-10 

Male ICR mice (4 weeks old) were infected with HSV type 1 (1 9 10 6 plaque-forming units/ml, F strain) grown in Vero cells as described previously. 16 The virus was inoculated twice into mice at a frequency of 10 days. After the second HSV inoculation, mice were observed from week 4 to week 32. Animals were handled in accordance with guidelines provided by the Institutional Animal Care and Use Committee of Ajou University School of Medicine (AMC-2016-0010).

Among all the mice infected with HSV, 15% developed BD-like symptoms including skin ulcerations, skin pustules, genital ulcerations, erythema, oral ulceration, ear inflammation, arthritis, genital ulcerations, red eye (left, right), reduced vision (left, right), weight loss and facial swelling. Oral, genital and skin ulcers, and eye symptoms were classified as major symptoms. Other symptoms were identified as minor symptoms. Mice displaying more than one major and one minor symptom were diagnosed with BD. Each symptom score was assigned a single point. The sum of all symptom scores was used to determine the severity of BD. Disappearance of symptoms or ≥20% decrease in lesion size was classified as symptom improvement. The disease severity score of BD was calculated according to the BD activity index outlined in the BD Activity Form ( www.behcet.ws/ pdf/BehcetsDiseaseActivityForm.pdf). HSV-inoculated, but asymptomatic, healthy mice (BDN mice) served as the control group, as described previously.

Peripheral blood mononuclear cells and LN cells were isolated from mice. Erythrocytes were eliminated with ammonium-chloride-potassium solution and washed with phosphate-buffered saline (PBS) followed by surface staining of 1 9 10 6 cells with mouse CCR1 allophycocyaninconjugated antibody (cat# FAB5986A; R&D Systems, Minneapolis, MN) for 30 min at 4°in the dark. For intracytoplasmic staining, cells were fixed in intracytoplasmic fixation buffer for 20 min at room temperature. After washing twice with a permeabilization buffer, 1 9 10 6 cells were stained with an anti-mouse CCR1 antibody, followed by analysis of these cells with a flow cytometer (FACS Canto II; Becton Dickinson, San Jose, CA).

Fresh PBMC were washed twice with cold PBS and lyzed with lysis buffer (50 mM Tris-Cl, pH 7Á4, 0Á15 M NaCl, 1 mM EDTA, 1% Triton X-100, 10 lg/ml each of aprotinin and leupeptin, and 1 mM phenylmethylsulphonyl fluoride). The protein (30 lg) lysate was electrophoresed on a 10% sodium dodecyl sulfate-polyacrylamide gel. The proteins were transferred onto nitrocellulose membranes (Protran; GE Healthcare Life Sciences, Chicago, IL, USA) and subjected to immunoblot analysis using antibodies. The immunoblots were developed with the enhanced chemiluminescence system (GE Healthcare Life Sciences). Antibody against CCR1 (MAB5986) was purchased from R&D Systems and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (sc-32233) was from Santa Cruz Biotechnology, Inc. (Dallas, TX).

Normal and BD mice were treated in vivo with PBS, interleukin-10 (IL-10) (50 pg/mouse/day) (cat# CYT-497; Prospecbio, Ness-Ziona, Israel), granulocyte-macrophage colony-stimulating factor (GM-CSF) (200 pg/mouse/day) (cat# CYT-222; Prospecbio), chemokine CC motif ligand 3 (CCL3) (100 pg/mouse/day) (cat# CHM-320; Prospecbio), or anti-CCL3 antibody (20 ng/mouse/day) (cat# AF-450-NA; R&D Systems) for five consecutive days by intraperitoneal administration. Normal mice were 3Á5 weeks old. PBMC and LN cells were isolated 3 hr after the last medication for analysis of CCR1 + cells by flow cytometry. BX471, a CCR1 antagonist (cat# SML0020; Sigma-Aldrich, St Louis, MO), was intraperitoneally administered to normal and BD mice at 0Á5 mg/ mouse three times (every other day). BD symptoms were observed before and after treatment. Images were obtained to document the treatment-related changes.

Mice were treated orally with PBS, colchicine (2 lg/mouse/ day), or pentoxifylline (400 lg/mouse/day) for five consecutive days. Changes in symptoms were monitored. At 3 hr after the last medication, the mice were killed by intramuscular injection into the hind leg with a ketamine/xylazine cocktail (15 mg/kg ketamine and 10 mg/kg xylazine). PBMC and LN cells were isolated for analysis of CCR1 + cells.

Department of Dermatology, Ajou University Hospital. Sampling from patients with BD was random when the patients first arrived. Clinical characteristics and therapeutic histories of these patients are shown in Tables 1 and 2. According to the International Study Group for BD criteria, the presence of any two of the following symptoms, in addition to recurrent oral ulcerations, is considered as BD diagnosis: recurrent genital ulceration, cutaneous erythema nodosum, large-vessel vasculitis, arthritis, uveitis, and/or a positive pathergy test. The disease severity score was calculated from Behc ßet's disease current activity form 2006 (http://www.behcetdiseasesociety.org/behcetwsData/Uploads /files/BehcetsDiseaseActivityForm.pdf). Patients with active BD (n = 12, 11 men, one woman, 45Á0 AE 10Á2 years) were enrolled. Gender differences among BD patients with mucocutaneous manifestations were inconsistent among different nationalities. 20 Informed consent was obtained from patients before the study. The healthy control group (n = 12, 48Á8 AE 9Á2 years) comprised one man and 11 women. Serum was provided by the Biobank of Ajou University Hospital, a member of the Korea Biobank Network. This study was approved by the ethics committee of Ajou University Medical Center Institutional Review Board (AJIRB-GN3-07-098) and all experiments were conducted according to the Institutional Review Board permitted protocol.

Peripheral blood was collected in EDTA-coated test tubes and centrifuged at 1000 g for 5 min at 20°. The supernatant was stored at À70°until used. CCL3 levels were measured in plasma using a commercial enzymelinked immunosorbent assay (ELISA) kit (Cat# BMS2029INST; Thermo Fisher Scientific, Waltham, MA) following the manufacturer's instructions. For ELISA analysis, each sample was applied in duplicate wells and three times in different ELISA plates.

The data and statistical analysis complied with the recommendations of experimental design and analysis in pharmacology.

Flow cytometric analysis was performed to analyze the surface and cytoplasm CCR1 + cells stained with anti-CCR1 antibody for PBMC and LN cells isolated from normal (n = 10), BDN (n = 10), and BD (n = 10) mice. Frequencies of CCR1 + cells on the surface of PBMC were significantly down-regulated in BD mice compared with those in normal mice (7Á06 AE 1Á8% versus 11Á11 AE 2Á5%, P = 0Á0005) or BDN mice (7Á06 AE 1Á8% versus 10Á58 AE 1Á92%, P = 0Á0006). Frequencies of CCR1 + cells on the surface of LN cells were also down-regulated in BD mice compared with normal mice (10Á6 AE 3Á2% versus 12Á99 AE 1Á5%, P = 0Á05) or BDN mice (10Á6 AE 3Á2% versus 11Á12 AE 2Á1%, P = 0Á67) (Fig. 1a) . The frequencies of cytoplasm staining in CCR1 + PBMC were significantly lower in BD mice than in normal mice (32Á08 AE 16Á3% versus 73Á6 AE 3%, P < 0Á0001) or BDN mice (32Á08 AE 16Á3% versus 58Á4 AE 11Á05%, P = 0Á0005). The frequencies of CCR1 + LN cells were also significantly lower in BD mice than in normal mice (58Á04 AE 22Á39% versus 82Á14 AE 8Á15%, P = 0Á005). There were no differences in frequencies of CCR1 + cells between BD and BDN mice (58Á04 AE 22Á39% versus 59Á10 AE 27Á6, P = 0Á9) (Fig. 1b) . Representative histograms of surface staining results are presented in Fig. 1 (c). Figure 1 (d) shows the Western blot analysis for CCR1 expression in whole PBMC lysates in normal, BDN and BD mice (n = 3 in each group). The expression ratio of CCR1 compared with GAPDH was not different between BDN (1Á42 AE 0Á34) and BD (1Á48 AE 1Á15) mice ( Fig. 1e , n = 7). This means the entire amount of CCR1 in PBMC was not correlated with the symptoms.

Interleukin-10 synergistically enhanced GM-CSF-induced CCR1. 21 GM-CSF is known as a CCR1-enhancing cytokine. 22 Therefore, IL-10 and GM-CSF were administered to normal and BD mice. To determine the functional doses in mice in vivo, IL-10 and GM-CSF were injected into 3Á5-week-old normal mice intraperitoneally at the following doses: IL-10 (25, 50 and 100 pg) and GM-CSF (50, 100 and 200 pg). At 3 hr after the last treatment, PBMC were isolated from mice for flow cytometry to measure the frequencies of CCR1 + cells on the surface and cytoplasm.

In mice treated with 50 pg of IL-10 (n = 13), the frequencies of surface CCR1 + cells were significantly up-regulated in PBMC compared with PBS-treated control mice (n = 5) (13Á14 AE 0Á9% versus 11Á0 AE 0Á3%, P = 0Á009). Treatment with 25 pg of IL-10 (n = 9) did not affect the frequencies of CCR1 + cells compared with PBS-treated control mice (n = 5) (11Á74 AE 0Á96% versus 11Á0 AE 0Á3%, P = 0Á47). Treatment with 100 pg of IL-10 (n = 6) up-regulated the frequencies of CCR1 + cells compared with PBS-treated control mice (n = 5), although the difference was not statistically significant (13Á65 AE 2Á05% versus 11Á0 AE 0Á3%, P = 0Á18). The frequencies of cytoplasm CCR1 + PBMC were slightly increased in mice treated with 50 pg of IL-10 and 100 pg of IL-10 compared with those in PBS-treated control mice (62Á575 AE 9Á89% versus 56Á05 AE 23Á12%, P = 0Á6; 58Á8 AE 23Á33% versus 56Á05 AE 23Á12%, P = 0Á9), although the differences were not statistically significant (Fig. 2a) .

In normal mice exposed to 200 pg of GM-CSF (n = 5), the frequencies of surface CCR1 + PBMC were up-regulated compared with PBS-treated control mice (15Á65 AE 1Á4% versus 11Á0 AE 0Á42%, P = 0Á05). In mice treated with 100 pg of GM-CSF (n = 6), the frequencies of CCR1 + cells were higher compared with the levels in PBS-treated control mice (n = 5) (13Á75 AE 1Á34% versus 11Á0 AE 0Á3%, P = 0Á11). However, the difference was not statistically significant. Mice treated with 50 pg of GM-CSF (n = 6) showed frequencies of CCR1 + cells similar to those in PBS-treated control mice (n = 5). In the cytoplasm of PBMC, frequencies of CCR1 + cells in mice treated with GM-CSF at 50, 100 and 200 pg (62Á25 AE 3Á18%; 63Á95 AE 1Á9%; 64Á7 AE 1Á5%, respectively) were not significantly (P > 0Á05) different compared with those in the PBS control group (56Á05 AE 23Á12%) (Fig. 2b) .

Interleukin-10 and GM-CSF up-regulate frequencies of CCR1 + cells in BD mice According to functional doses of IL-10 and GM-CSF in normal mice, 50 pg/mouse/day of IL-10 and 200 pg/ mouse/day of GM-CSF were administered to BD mice to up-regulate CCR1 + cells. After five consecutive days of treatment to BD mice, PBMC and LN cells were subjected to surface and cytoplasm staining for FACS analysis. In the surface of PBMC, the frequencies of CCR1 + cells in BD mice treated with IL-10 (n = 7) and GM-CSF (n = 7) showed significant up-regulation compared with those in PBS-treated BD mice (n = 10) (IL-10 versus PBS: 13Á61 AE 2Á5% versus 7Á06 AE 1Á8%, P < 0Á0001; GM-CSF versus PBS: 9Á0 AE 1Á3% versus 7Á06 AE 1Á8%, P = 0Á03). The surface CCR1 + LN cells were significantly up-regulated compared with PBS-treated BD mice (IL-10 versus PBS: 17Á6 AE 2Á7% versus 10Á6 AE 3Á23%, P = 0Á0002; GM-CSF versus PBS: 15Á4 AE 1Á6% versus 10Á6 AE 3Á23%, P = 0Á003) (Fig. 2c) . In the cytoplasm, CCR1 + PBMC also increased after treatment with IL-10 (54Á67 AE 5Á00% versus 32Á04 AE 16Á3%, P = 0Á02) and GM-CSF (82Á1 AE 6Á4% versus 32Á08 AE 16Á3%, P = 0Á001) compared with PBS-treated BD mice. Cytoplasm CCR1 + cells in LN were increased only by GM-CSF (77Á85 AE 5Á9% versus 58Á04%, P = 0Á04). Frequencies of cytoplasm CCR1 + LN cells were not changed after IL-10 treatment (Fig. 2d ). IL-10 and GM-CSF up-regulated the frequencies of CCR1 + cells in both normal and BD mice.

CCL3 down-regulates the expression of CCR1 + cells in normal mice CCR1 has multiple ligands. CCL3 is one of its ligands for CCR1 down-regulation function. 23 To determine whether CCR1 was regulated by CCL3, CCL3 was intraperitoneally injected into normal mice. Frequencies of CCR1 + PBMC and LN cells were decreased after CCL3 treatment. In surface staining of PBMC, treatment with 100 pg of CCL3 (n = 6) significantly decreased the frequencies of CCR1 + cells compared with PBS control (n = 5) (4Á62 AE 1Á3% versus 12Á92 AE 1Á89%, P = 0Á0002). Treatment with 50 pg CCL3 decreased frequencies of CCR1 + cells, although the decrease was not significant (9Á05 AE 2Á7% versus 12Á92 AE 1Á89%, P = 0Á06). In surface staining of LN cells, treatment with CCL3 at 100 pg (n = 6) significantly down-regulated the frequencies of CCR1 + cells compared with PBS control (n = 5) (9Á42 AE 1Á32% versus 13Á15 AE 1Á7%, P = 0Á009). Treatment with CCL3 50 pg (n = 6) resulted in similar frequencies of CCR1 + cells compared with PBS-treated control mice (Fig. 3a) .

The frequencies of cytoplasm CCR1 + PBMC after treatment with CCL3 at 50 and 100 pg were significantly decreased to (50Á95 AE 4Á3%, P < 0Á0001) and (33Á9 AE 4Á4%, P < 0Á0001) compared with PBS control (74Á05 AE 3Á4%). Cytoplasm CCR1 + LN cells were significantly down-regulated in mice treated with 50 pg of CCL3 (25Á65 AE 1Á34%, P < 0Á0001) or 100 pg of CCL3 (39Á48 AE 2Á4%, P < 0Á0001) compared with PBS-treated control mice (73Á75 AE 1Á4%) (Fig. 3b) . A histogram of surface and cytoplasm CCR1 + PBMC after treatment with CCL3 is presented in Fig. 3(c) .

To down-regulate CCR1 + cells in BD mice, CCL3 100 pg/ day was administered to BD mice (n = 11) for five consecutive days. Frequencies of surface CCR1 + PBMC were significantly lower compared with PBS-treated BD mice (n = 10) (4Á59 AE 1Á36% versus 7Á06 AE 1Á8%, P = 0Á003). The frequencies of surface CCR1 + LN cells were not different after CCL3 treatment (Fig. 4a) . Cytoplasm CCR1 + LN cells were down-regulated significantly after CCL3 treatment compared with PBS control (38Á38 AE 7Á74% versus 58Á04 AE 22Á39%, P = 0Á01). However, CCR1 + expression was not changed in PBMC cytoplasm (Fig. 4b) . Treatment with CCL3 deteriorated BD symptoms in 10 (62Á5%) of 16 BD mice and the disease severity score increased from 2Á73 AE 0Á47 to 3Á2 AE 1Á00 after 5 days of treatment. Four BD mice showed new skin ulcer and arthritis, and the remaining BD mice showed increased ulcer size.

BX471, a CCR1 antagonist, does not down-regulate CCR1 + cells in BD mice BX471 was developed as a CCR1 antagonist to treat several inflammatory diseases, including rheumatoid arthritis. 12 BX471 was administered to BD mice to downregulate CCR1. BX471-treated BD mice (n = 3) showed 8Á23 AE 6Á17% of surface CCR1 + PBMC, 11Á53 AE 3Á71% of surface CCR1 + LN cells, 54Á53 AE 14Á59% of cytoplasm PBMC, and 67Á17 AE 11Á49% of cytoplasm LN cells. In BD mice, BX471 did not play a role in the down-regulation of CCR1 + cells (Fig. 4a,b) . In normal mice, BX471treated mice showed higher frequencies of surface CCR1 + PBMC than in PBS-treated normal mice (17Á22 AE 8Á66% versus 12Á15 AE 7Á92%, P = 0Á3) and LN cells (15Á66 AE 1Á14% versus 13Á15 AE 1Á73%, P = 0Á05). Inhibition of CCR1 expression by BX471 was only found in the cytoplasm of PBMC (BX471 versus PBS: 65Á94 AE 5Á12% versus 74Á05 AE 3Á47%, P = 0Á02) (Fig. 4c,d) .

Colchicine and pentoxifylline are the most frequently prescribed medications for BD. 24 They are also used in BD mice. 25 To determine the correlation between CCR1 expression and these two agents, colchicine (n = 7) and pentoxifylline (n = 7) were administered to 4-week-old normal mice. The surface expression of CCR1 in PBMC was significantly up-regulated compared with PBS-treated normal mice (n = 10) (colchicine versus PBS: 16Á02 AE 2Á2% versus 11Á11 AE 2Á39%, P = 0Á0006; pentoxifylline versus PBS: 17Á02 AE 3Á8% versus 11Á11 AE 2Á2%, P = 0Á001). Colchicine significantly up-regulated the expression of CCR1 on the surface of LN cells, compared with PBS-treated normal mice (16Á02 AE 2Á2% versus 12Á99 AE 1Á56%, P = 0Á005). Pentoxifylline also up-regulated the expression of CCR1 compared with PBS-treated normal mice, although the up-regulation was not statistically significant (14Á8 AE 3Á6% versus 12Á99 AE 1Á56%, P = 0Á18) (Fig. 5a) . Colchicine and pentoxifylline significantly down-regulated the expression of cytoplasm CCR1 + PBMC (59Á37 AE 11Á5%, P = 0Á002; 59Á7 AE 18Á8%, P = 0Á03, respectively) compared with PBS control (73Á65 AE 3Á0%). Cytoplasm CCR1 expression in LN cells was not altered under colchicine or pentoxifylline treatment (Fig. 5b) .

Frequencies of CCR1 + cells were determined after BD mice were treated with medication. Treatment with colchicine (n = 7) or pentoxifylline (n = 7) significantly upregulated CCR1 surface expression in PBMC of BD mice compared with PBS-treated BD mice (n = 10) (15Á92 AE 4Á5% versus 7Á06 AE 1Á8%, P < 0Á0001; 19Á083 AE 3Á4% versus 7Á06 AE 1Á8%, P < 0Á0001, respectively). The frequencies of surface CCR1 + LN cells were also increased significantly by colchicine or pentoxifylline compared with the PBS-treated BD mice (17Á68 AE 7Á9% versus 10Á6 AE 3Á23%, P = 0Á02; 21Á36 AE 4% versus 10Á6 AE 6Á9%, P < 0Á0001, respectively) (Fig. 5c ). In the cytoplasm of PBMC, treatment with colchicine and pentoxifylline increased the frequencies of CCR1 + cells. However, only pentoxifylline treatment resulted in a significant increase (77Á4 AE 6Á97% versus 32Á08 AE 16Á39%, P < 0Á0001), colchicine or pentoxifylline did not affect the frequency of cytoplasm CCR1 + LN cells compared with PBS-treated BD mice (Fig. 5d) . The histogram of CCR1 + expression in the surface and cytoplasm of PBMC after treatment with colchicine and pentoxifylline is presented in Fig. 5(e) . Results show that the frequencies of surface CCR1 + expression rather than cytoplasm expression strongly correlated with the regulation of BD symptoms.

To determine whether CCR1 was regulated by CCL3 inhibition, anti-CCL3 antibody was intraperitoneally injected into normal mice. Frequencies of CCR1 + PBMC and LN cells were increased after anti-CCL3 antibody treatment. In surface staining of PBMC, treatment with anti-CCL3 antibody at 1-200 ng significantly increased frequencies of CCR1 + cells compared with PBS-treated normal mice (1 ng, 12Á84 AE 1Á98%, P = 0Á009; 2 ng, 13Á37 AE 2Á28%, P = 0Á002; 20 ng, 15Á28 AE 2Á57%, P < 0Á0001; 50 ng, 16Á92 AE 1Á32%, P < 0Á0001; 200 ng, 15Á6 AE 2Á12%, P = 0Á0005; versus PBS, 8Á3 AE 2Á04%). In surface staining of LN cells, treatment with anti-CCL3 antibody significantly up-regulated frequencies of CCR1 + LN cells compared with PBS-treated normal mice (1 ng, 15Á16 AE 2Á83%, P < 0Á0001; 2 ng, 17Á62 AE 4Á24%, P < 0Á0001; 20 ng, 19Á4 AE 1Á59%, P < 0Á0001; 50 ng, 19Á82 AE 1Á76%, P < 0Á0001; 200 ng, 16Á75 AE 5Á58%, P = 0Á0008; versus PBS, 8Á72 AE 1Á21%) (Fig. 6a) . In the cytoplasm, frequencies of CCR1 + PBMC after treatment with anti-CCL3 antibody at 1-200 ng were not altered significantly in PBMC cytoplasm compared with PBStreated normal mice (1 ng, 64Á36 AE 11Á82%; 2 ng, 55Á75 AE 3Á33%; 20 ng, 53Á94 AE 5Á04%; 50 ng, 64Á65 AE 8Á83%; 200 ng, 40Á05 AE 2Á33%; versus PBS, 52Á45 AE 13Á42%) (Fig. 6b) . Cytoplasm CCR1 + LN cells were significantly up-regulated in mice treated with 1 ng of anti-CCL3 antibody (42Á12 AE 8Á93%, P = 0Á02) or 200 ng of anti-CCL3 antibody (59Á0 AE 7Á77%, P = 0Á0002) compared with PBS-treated normal mice (30Á0 AE 7Á27%). Treatment with 2, 20 and 50 ng of anti-CCL3 did not yield significant changes compared with PBS-treated normal mice (Fig. 6b) .

To up-regulate CCR1 + cells in BD mice, anti-CCL3 antibody 20 ng/day was administered to BD mice (n = 16) for five consecutive days. The frequencies of CCR1 + expression on the surface of PBMC were significantly increased compared with those in PBS-treated BD mice (n = 10) (15Á61 AE 2Á92% versus 7Á92 AE 2Á61%, P < 0Á0001). In LN cells, frequencies of surface CCR1 + expressions were significantly increased after anti-CCL3 antibody treatment (22Á8 AE 2Á7% versus 10Á6 AE 3Á1%, P = 0Á0001) (Fig. 7a) . In the cytoplasm of PBMC, the frequencies of CCR1 expression after treatment with anti-CCL3 antibody were up-regulated significantly compared with PBS control (51Á42 AE 13Á08% versus 32Á11 AE 16Á40%, P < 0Á0001). However, the cytoplasm CCR1 + LN cells were down-regulated after treatment with anti-CCL3 antibody compared with PBS control (40Á62 AE 7Á81% versus 58Á04 AE 22Á43%, P = 0Á008; Fig. 7b ). Anti-CCL3 antibody treatment improved BD symptoms in 10 (50Á0%) of 20 BD mice on day 5 after initiation with anti-CCL3 antibody treatment. The list of improved mice is provided in the Supplementary material (Table S1 ). The disease severity score in BD mice changed from 3Á1 AE 0Á3 to 2Á45 AE 0Á68 on day 5 with symptom improvement after anti-CCL3 antibody treatment (P < 0Á0001). Disease severity score was also significantly varied between CCL3-treated BD mice (3Á2 AE 1Á0) and anti-CCL3 antibody-treated BD mice (2Á45 AE 0Á68) on day five (P = 0Á004) (Fig. 7c ). Figure 7(d) show the changes in symptoms after treatment with CCL3 or anti-CCL3 antibody in BD mice.

The levels of CCL3 in patients with active BD (76Á88 AE 74Á48 pg/ml) were higher than in patients with inactive BD (24Á58 AE 7Á54 pg/ml, P = 0Á09) and healthy control individuals (22Á82 AE 7Á87 pg/ml, P = 0Á02) (Fig. 8 ).

This study quantitatively analyzed the expression of chemokine receptors in PBMC and LN cells of BD mice. Our results suggest that BD-like symptoms were correlated with frequencies of CCR1 + cells. Percentages of CCR1 + cells were significantly down-regulated in BD mice compared with normal or BDN mice. Cytokine IL-10and GM-CSF-treated BD mice exhibited significant upregulation of CCR1 + cells compared with PBS-treated BD mice. CCR1 ligand CCL3-treated BD mice showed significant down-regulation of CCR1 + cells compared with PBS- treated BD mice. Ten of 16 CCL3-treated BD mice showed deteriorated BD symptoms. Anti-CCL3 antibody treatment improved BD symptoms, decreased the disease severity score, and up-regulated CCR1 + cells significantly compared with PBS-treated BD mice. Treatment of BD mice with colchicine and pentoxifylline significantly up-regulated CCR1 + cells compared with PBS treatment. Frequencies of CCR1 + cells were strongly associated with symptoms in BD mice. Chemokine receptors are essential moderators of leukocyte trafficking in inflammatory diseases. CCR1 may be a strong therapeutic target in a variety of diseases. 26 CCR1 has been shown to play a role in recruiting monocytes and Th1 cells according to active inflammation. 27 CCR1 and its ligands are associated with the development of experimental arthritis. In rheumatoid arthritis, CCR1 is an efficient therapeutic target because it mediates the regulation of tumor necrosis factor-a and IL-10. 28 However, in patients with BD, the frequencies of CCR1 + cells are decreased in patients with active BD than in normal controls, even though the difference was not statistically significant. 29 Similarly, this study also shows that the frequencies of CCR1 + cells in BD mice were down-regulated compared with the control mice. Down-regulated CCR1 expression has been reported after infection with Leishmania infantum 30 or coronavirus. 31 Correlation between HSV infection and CCR1 expression does not show consistent results. 32 Chemokine CCL3 expression has been reported in arthritic inflammation. 34 CCL3 recruits inflammatory leukocytes by binding to CCR1. 35 It affects chronic joint inflammation. 36 Neutralizing antibodies to CCL3 alleviate inflammation. 37 Higher serum levels of CCL3 have been found in patients with active BD than in patients with inactive stages of BD. 38 Results of the present study demonstrate that treatment with CCL3 deteriorated symptoms in BD mice and down-regulated the frequencies of CCR1 + cells. Increased CCL3 expression exacerbates BD symptoms through down-regulation of CCR1.

Interleukin-10 is known as a CCR1 stimulator. 39 It is mainly expressed in monocytes, macrophages, Th2 cells, and B cells. IL-10 is one of the key anti-inflammatory cytokines expressed in the human immune response. It is a strong inhibitor of Th1 cytokines IL-2 and interferonc. 40, 41 Anti-inflammatory cytokine IL-10 suppresses proinflammatory cytokines and protects the host against tissue damage. 42 In patients with BD, IL-10 polymorphisms have been identified. 43, 44 Such gene variation might be correlated with insufficient expression of IL-10. Results of the present study show that IL-10 up-regulated the frequencies of CCR1 + cells in BD mice compared with PBS control. IL-10 and GM-CSF also synergistically increased the frequencies of CCR1 + cells in BD mice.

Granulocyte-macrophage colony-stimulating factor is a stimulator of CCR1 expression. 22 It enhances the maturation of dendritic cells and plays a role in recruiting circulating neutrophils, monocytes and lymphocytes for host defense. 45 Different types of inflammatory and immune cells such as dendritic cells, monocytes, neutrophils, microglia and macrophages are modulated by GM-CSF under autoimmune conditions. 46 GM-CSF may influence chronic inflammatory diseases such as arthritis, 47 experimental autoimmune encephalitis 48 and airway inflammation. 49 GM-CSF also enhances resistance to viral infection 50 and bacterial translocation. 51 In patients with BD, GM-CSF transcription was down-regulated more than in controls. 52 However, the protein expression or serum levels of GM-CSF in patients with BD have yet to be elucidated. According to a case report, intra-lesional injection with recombinant human GM-CSF induces wound healing in genital ulcers of BD. 53 GM-CSF also enhances CCR1 expression. 21, 22 Our data demonstrated that treatment with GM-CSF significantly up-regulated CCR1 + expression in PBMC and LN cells.

BX471 was developed as a potent antagonist against CCR1. 54 BX471 treatment attenuated systemic inflammation of sepsis, 55 nephritis, 56 arthritis 57 and myocarditis. 58 In our study, BX471 was administered to BD mice to confirm the correlation of CCR1 expression with BD by inhibiting CCR1. BX471 treatment failed to inhibit the frequencies of surface or cytoplasm CCR1 + PBMC and LN cells in BD mice. In normal mice, BX471 inhibited the expression of CCR1 only in the cytoplasm of PBMC.

These results indicate that BX471 treatment failed to adequately inhibit CCR1 + cells in vivo, which partly explains why clinical trials of BX471 inhibition of CCR1 were discontinued.

In conclusion, our study demonstrated down-regulated frequencies of CCR1 + cells, which were closely correlated with BD symptoms and the expression of CCR1 + cells was controlled by cytokine IL-10, GM-CSF and ligand CCL3. Even though BD is a multi-factorial inflammatory disease associated with immune dysregulation, treatment with single chemokine or chemokine receptor alone contributes to immune regulation resulting in the control of systemic symptoms of BD.

Two-stage association study in Chinese Han identifies two independent associations in CCR1/CCR1 locus as candidate for Behc ßet's disease susceptibility

Genome-wide association analysis identifies new susceptibility loci for Behc ßet's disease and epistasis between HLA-B*51 and ERAP1

Preparation of specific polyclonal antibodies to a C-C chemokine receptor, CCR3, and determination of CCR3 expression on various types of leukocytes

Human lung dendritic cells have an immature phenotype with efficient mannose receptors

Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1

Up-regulation of CCR6 and CCR6 and induction of chemotaxis to CC chemokines by IFN-c in human neutrophils

Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis

Expression and regulation of CCR8 by airway smooth muscle cells in asthma

CCR9 inhibition ameliorates the progression of lupus nephritis in NZB/W mice

Airway remodeling is absent in CCR10 -/-mice during chronic fungal allergic airway disease

CCR11/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation

Chemokine receptor antagonists: overcoming developmental hurdles

Detection of RNA complementary to herpessimplex virus in mononuclear cells from patients with Behc ßet's syndrome and recurrent oral ulcers

CD4 and CD8 cell responses to herpes simplex virus in Behc ßet's disease

durch ein virus verursachte geschw€ ure am mund, am auge und an den genitalien

Behc ßet's disease-like symptoms induced by the Herpes simplex virus in ICR mice

Learning from HSV-infected mice as a model of Behc ßet's disease

Immunopathogenic role of herpes simplex virus in Behc ßet's disease

Serum reactivity against herpes simplex virus type 1 UL48 protein in Behc ßet's disease patients and a Behc ßet's disease-like mouse model

The spectrum of mucocutaneous manifestations in Adamantiades-Behc ßet's disease in Greece

IL-10 synergistically enhances GM-CSF-induced CCR21 expression in myelomonocytic cells

Granulocyte-macrophage colony stimulating factor up-regulates CCR22 in human neutrophils

Differential pattern of CCR23 internalization in human eosinophils: prolonged internalization by CCL5 in contrast to CCL3

Treatment of Behc ßet's disease

The relevance of miRNA-21 in HSV-induced inflammation in a mouse model

Chemokines and disease

The role of chemokines in the recruitment of lymphocytes to the liver

Pharmacological blockade of CCR28 ameliorates murine arthritis and alters cytokine networks in vivo

Abnormal expression of chemokine receptors in Behc ßet's disease: relationship to intracellular Th1/ Th2 cytokines and to clinical manifestations

Reduced expression of the chemokine receptor CCR30 in human macrophages and U-937 cells in vitro infected with Leishmania infantum

CCR31 deficiency increases susceptibility to fatal coronavirus infection of the central nervous system

Persistent expression of chemokine and chemokine receptor RNAs at primary and latent sites of herpes simplex virus 1 infection

Blocking CC chemokine receptor (CCR) 1 and CCR33 during herpes simplex virus type 2 infection in vivo impairs host defence and perturbs the cytokine response

Genome-wide haplotype association analysis and gene prioritization identify CCL3 as a risk locus for rheumatoid arthritis

Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease

An essential role for CCL3 in the development of collagen antibody-induced arthritis

Crucial role of CCL3/MIP-1a in the recurrence of autoimmune anterior uveitis induced with myelin basic protein in Lewis rats

Enhanced production of macrophage inhibitory protein-1a in patients with Behc ßet's disease

IL-10 enhances CCL2 release and chemotaxis induced by CCL16 in human monocytes

IL-10 inhibits cytokine production, vascular leakage, and swelling during T helper 1 cell-induced delayed-type hypersensitivity

The regulation of IL-10 production by immune cells

Interleukin-10 and immunity against prokaryotic and eukaryotic intracellular pathogens

Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behc ßet's disease susceptibility loci

Genomewide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behc ßet's disease

Granulocyte-macrophage colonystimulating factor (GM-CSF) and T-cell responses: what we do and don't know

GM-CSF: an immune modulatory cytokine that can suppress autoimmunity

as therapeutic targets in rheumatoid arthritis

GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis

Intranasal exposure of mice to house dust mite elicits allergic airway inflammation via a GM-CSF-mediated mechanism

GM-CSF in the lung protects against lethal influenza infection

Effect of granulocyte-macrophage colony stimulating factor on bacterial translocation after experimental obstructive jaundice

Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in Behc ßet's disease

Local intralesional therapy with rhGM-CSF for a large genital ulcer in Behc ßet's disease

Predictions of CCR54 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation

Treatment with BX471, a CC chemokine receptor 1 antagonist, attenuates systemic inflammatory response during sepsis

Late onset of treatment with a chemokine receptor CCR56 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice

Why CCR57 and CCR57 blockade failed and why CCR57 blockade might still be effective in the treatment of rheumatoid arthritis

A CCR58 antagonist prevents the development of experimental autoimmune myocarditis in association with T cell inactivation

The authors declare no conflicts of interest.

Additional Supporting Information may be found in the online version of this article:Table S1 List of symptoms in anti-CCL3 antibody-treated Behc ßet's disease mice.